Wednesday, 23 February 2011


Alan Barbour's patent tells the tale

This one statement is powerful, contradicting the stance that Barbour and the IDSA Lyme Disease Guideline supporters have made for years.

Alan Barbour in one paragraph summarizes strain variation, immune system evasion, persistent infection, failure of Lyme tests and the uniqueness of Borrelia amongst other pathogens.

"This mechanism of genetic switching appears to be different from any other antigenic variation mechanism described in bacteria or protozoa and has important implications in Lyme disease. By combining different regions of the silent vls cassettes, it is possible for many different vlsE serotypes to coexist the same patient. It may be impossible for the host to mount a protective response against any one of these clonal populations, because of the small number of each type. Even mounting a response against one serotype would not protect against rapidly evolving, new serotypes."

Read an excellent report on this patent by Camp Other Blog, helpful for those who are not able to understand the technicalities, at the link here

To access the full patent click here

Another extract:-

[0006] These organisms are closely related and cause similar manifestations with multiple stages: an expanding rash at the site of the tick bite (erythema migrans), fever, lymphadenopathy, fatigue, and malaise; effects of disseminated infection, including carditis, meningoradiculitis, and polyarthritis; and chronic manifestations including arthritis and neurologic disorders. Lyme disease is often difficult to diagnose because of shared manifestations with other disorders, and it can also be refractory to treatment during late stages of the disease."

My Chronic symptoms of Arthritis, Muscle Weakness, Fatigue and peripheral neuropathies turned out to be Lyme Disease and on long term antibiotics have all resolved, how many more patients with similar symptoms as a result of a tick bite could be helped on just simple antibiotics?

I posted earlier on Barbour here

No comments:

Post a Comment